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ABSTRACT
Overexpression of protein tyrosine phosphatase PTP4A oncoproteins is common
in many human cancers and is associated with poor patient prognosis and survival.
We observed elevated levels of PTP4A3 phosphatase in 79% of human ovarian
tumor samples, with significant overexpression in tumor endothelium and pericytes.
Furthermore, PTP4A phosphatases appear to regulate several key malignant
processes, such as invasion, migration, and angiogenesis, suggesting a pivotal
regulatory role in cancer and endothelial signaling pathways. While phosphatases
are attractive therapeutic targets, they have been poorly investigated because of
a lack of potent and selective chemical probes. In this study, we disclose that a
potent, selective, reversible, and noncompetitive PTP4A inhibitor, JMS-053, markedly
enhanced microvascular barrier function after exposure of endothelial cells to
vascular endothelial growth factor or lipopolysaccharide. JMS-053 also blocked the
concomitant increase in RhoA activation and loss of Rac1. In human ovarian cancer
cells, JMS-053 impeded migration, disrupted spheroid growth, and decreased RhoA
activity. Importantly, JMS-053 displayed anticancer activity in a murine xenograft
model of drug resistant human ovarian cancer. These data demonstrate that PTP4A
phosphatases can be targeted in both endothelial and ovarian cancer cells, and
confirm that RhoA signaling cascades are regulated by the PTP4A family.

INTRODUCTION

substantial advances in the development of kinasetargeted therapeutics, these agents have thus far had little
impact on ovarian cancer (OvCa) patient survival, which
remains stubbornly at ~45% five years after diagnosis.
OvCa tumors are genetically complex and lack common
molecular drivers [1]. Since protein tyrosine phosphatases
(PTPs) appear to have a major role in the malignancy of
cancer [2], we have initiated a program to develop small
molecule probes to explore new therapeutic opportunities.

Aberrant intracellular signaling is a recurrent feature
of human cancers that is often reflected in substantial
changes in pathways involving protein phosphorylation
and dephosphorylation. Most protein tyrosine kinases are
responsive to extracellular signals, but they are frequently
mutated or dysregulated, promoting uncontrolled
proliferation and enhanced cell survival. Despite
www.impactjournals.com/oncotarget

8223

Oncotarget

RESULTS

Studies with patient-derived tumor samples indicate
a high level of expression of protein-tyrosine phosphatase
4A (PTP4A, also known as PRL) family members, and
particularly PTP4A3 in ovarian cancers [3-6]. Elevated
PTP4A3 expression has also been correlated with poor
patient prognosis and metastatic processes in several
cancer types [6-8]. While definitive endogenous PTP4A
substrates have yet to be identified, genetic studies clearly
implicate PTP4A in important cancer-associated signaling
processes, thereby supporting a pivotal role for this PTP
family in tumorigenesis [9-13]. Excess PTP4A promotes
RhoA activation through a non-canonical interaction
with the Src homology 3 domain of p115 RhoGTPaseactivation protein [9]. PTP4A3 is highly expressed in the
tumor-associated endothelium [3, 14], which has a central
role in metastases formation and angiogenesis [12]. The
altered microenvironment in tumors, including high
concentrations of the potent vasodilator VEGF, creates
a dysfunctional endothelium, which loses critical barrier
properties. VEGF promotes the transcription of PTP4A3
through Myocyte Enhancer Factor 2C [15], and it has been
documented that the loss of PTP4A3 attenuates VEGFmediated vascular permeability in vivo [13]. The formation
of OvCa peritoneal ascites is driven by vasodilation
and loss of vascular membrane integrity, which enables
tumor cell dissemination [13, 16]. Therefore, PTP4A3
phosphatase appears to influence the function of both
tumor and stromal cells.
The interrogation of PTP4A3’s biochemical function
and ability to serve as a therapeutic target would be
greatly facilitated by potent and selective small molecule
inhibitors. Although several candidates have been studied,
including pentamidine, ginkgetin, sciadopitysin, emodin,
BR-1, and some cyano-2-ene esters, most are neither
potent (i.e., IC50>25 µM) nor specific for PTP4A3. Current
inhibitors are also frequently encumbered by structural
liabilities, such as redox, metal-chelating, and electrophilic
properties (reviewed in [17]). A thienopyridone was
previously found to be a sub-micromolar PTP4A3 inhibitor
(in vitro IC50~150 nM) with considerable selectivity
against 11 other phosphatases [18]. This compound
suppressed anchorage-independent cancer cell growth
in soft agar [18], but there is no available information
about its in vivo activity. Our group recently designed and
synthesized a novel iminothienopyridinedione, JMS-053,
which proved to be a potent PTP4A3 inhibitor (in vitro
IC50~20 nM) [19]. Herein, the biochemical properties of
JMS-053, including the inhibition of OvCa cell migration
and spheroid growth, and the attenuation of in vivo tumor
growth, are reported. Moreover, the discovery of a new
role for PTP4A3 in controlling microvascular endothelial
barrier function was also identified. Finally, JMS-053
served as a critical tool compound in identifying RhoA
functions as a distal signaling convergence point for
PTP4A activity in both endothelial and tumor cells.

www.impactjournals.com/oncotarget

Ptp4a3 is amplified in serous cystadenocarcinoma
and highly expressed in OvCa tumors
Ptp4a3 is located in chr8q24, which is one of the
most commonly amplified chromosomal regions in human
cancers, including OvCa, suggesting a fundamental role in
tumor maintenance or dissemination [20]. Previous studies
of PTP4A3 expression profiles in OvCa used small sample
sizes. Therefore, the most recent TCGA database from 594
patients (September 2017) (https://tcga-data. nci.nih.gov/
tcga/) was analyzed, and Ptp4a3 amplification in ~33%
of the ovarian serous cystadenocarcinomas (Figure 1A)
and exceptionally high mRNA expression compared to the
13,860 genes examined in the companion RNASeqV2 data
from 307 TCGA OvCa patients was confirmed (Figure
1B, Supplementary Figure 1A). Notably, PTP4A3 was
rarely deleted or mutated. Because an increase in PTP4A1
or PTP4A2 mRNA was not observed, we subsequently
focused primarily on PTP4A3 in OvCa.
Immunohistochemical
analysis
of
human
patient tumor samples from the University of Virginia
Biorepository revealed PTP4A3 protein overexpression
in 45/57 (79%) primary OvCa tumors (Table 1), as well
as in the tumor endothelium and pericytes (Figure 1C1D). These results provide further support that PTP4A3
overexpression occurs in human OvCa and add to
its attractiveness as a candidate for pharmacological
interrogation in both malignant and stromal populations
within OvCa tumors.

JMS-053 is a potent, specific, reversible, allosteric
inhibitor of PTP4A3 phosphatase activity
The recently synthesized small molecule JMS-053
has an in vitro IC50 against human recombinant PTP4A3
of 18 nM, and currently is the most potent known inhibitor
of this enzyme. It is a significant improvement over
thienopyridone, which has an IC50 of ~150 nM for PTP4A3
(Figure 2A-2B) [19]. A close structural analog of JMS053, JMS-038, was inactive at concentrations as high as
100 µM, and therefore serves as a useful negative control
compound (Figure 2A-2B). Furthermore, no structurally
similar compounds with a 2D Tanimoto score of ≥0.8 were
found during a search of the PubChem and ChemSpider
databases, supporting the structural uniqueness of the
JMS-053 chemotype. JMS-053 is a reversible PTP4A3
inhibitor, as indicated by dilution studies (Figure 2C).
Reversible inhibition further distinguishes JMS-053
from many other PTP inhibitors, which frequently are
irreversible, either because they form covalent adducts
or generate species that oxidize the catalytic Cys [17].
Similar to thienopyridone, JMS-053 behaved as a
8224

Oncotarget

noncompetitive inhibitor of the 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) substrate (Figure 2D.
Supplementary Figure 1B). JMS-053 also had significantly
improved in silico drug-like properties compared to the
less active thienopyridone (Supplementary Table 1).
Profiling JMS-053 against a panel of 25 other phosphatases
(Figure 3A-3C, Table 2) and 50 kinases (Supplementary
Table 2) showed that this chemotype was highly specific
for the PTP4A family despite its rather small mass. The
PTPs surveyed were broadly representative of the major
human superfamily members, including three receptor-like
PTPs, ten cytosolic PTPs, and five closely related dualspecificity phosphatases. This specificity was irrespective
of whether one compared the amino acids in the catalytic
domain (Figure 3A) or the full-length protein (Figure 3B-

3C). JMS-053 also inhibited the two homologous PTP4A
family members, PTP4A1 and PTP4A2, with IC50 values
of 50 ± 14 and 53 ± 8 nM, respectively. Because both
PTP4A1 and PTP4A2 also have oncogenic properties
and are overexpressed in cancer, a pan-PTP4A family
inhibition profile may be a valuable attribute for a small
molecule therapeutic [5, 17]. Comparatively minimal
inhibition was detected with the other phosphatases or
kinases using a 1 µM screening concentration, with the
exception of CDC25B and p38α, which were inhibited
by ~50%. Overall, JMS-053 showed at least a 20-fold
selectivity for the PTP4A enzymes.
Based on kinetics studies, the Ki of JMS-053 for
PTP4A3 was 18 nM. Initial attempts to co-crystalize
JMS-053 with PTP4A3, however, have been unsuccessful.

Figure 1: PTP4A3 expression is elevated in OvCa tumors. Panel A. The Ptp4a3 gene was amplified in 33% of the tumors of
OvCa patients found in the TCGA Provisional database (594 total patients). Panel B. PTP4A3 mRNA was the most abundant mRNA in
TCGA OvCa tumors as determined by RNAseq (307 OvCa patients). cBioPortal computes the relative expression of an individual gene in
the tumor to the gene’s expression distribution in a reference population. The reference population is defined as all samples that are diploid
for the gene in question or all profiled samples. Panel C. Immunohistochemical staining of OvCa patient tumor tissue showed enhanced
PTP4A3 protein expression. Panel D. Enhanced PTP4A3 protein expression of PTP4A3 was seen in OvCa vascular endothelial cells and
pericytes.
www.impactjournals.com/oncotarget
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Table 1: PTP4A3 protein expression in human patient samples as detected by
immunohistochemistry
Score
PTP4A3 (Positive/
Cancer
Total)
I
II
III
IV
High Grade Serous
Endometrioid
Mucinous
Other
Total

41/52
(79%)
2/2
(100%)
1/1
(100%)
1/2
(50%)
45/57
(79%)

11

11

14

16

0

1

0

1

0

0

1

0

1

1

0

0

12/57
(21%)

13/57
(23%)

15/57
(26%)

17/57
(30%)

Figure 2: Structure, inhibitory activity, mechanism of action, and PTP4A binding of JMS-053. Panel A. Chemical structure

of thienopyridone, JMS-053 and its inactive analog JMS-038. Panel B. PTP4A3 inhibition by JMS-053 using a full-length recombinant
human PTP4A3 and DiFMUP as the substrate. ■, JMS-053; ▲, JMS-038; ■, thienopyridone. Panel C. Reversible PTP4A3 inhibition by
JMS-053. Full length PTP4A3 was treated with a concentration of JMS-053 equal to the IC50 or 10-fold higher, namely 18 or 180 nM,
respectively. Pre-incubated (Pre-I) samples were exposed to a concentration of JMS-053 that was 10-fold higher than the IC50 for 30 min
and then diluted to 18 nM, (IC50). Enz, enzyme. Panel D. Lineweaver Burk plot indicated noncompetitive inhibition by JMS-053. Panels
B-D, Bars = SEM, N = 8. Panel E. Thermal shift assay for PTP4A3 protein (Tm = 50.5ºC) showing destabilization by 100 µM JMS-053
(Tm = 47.5ºC) and by 100 µM thienopyridone (Tm = 48.8oC). JMS-038 (100 µM) produced no significant thermal shift. Panel F. Proposed
noncompetitive binding mode of JMS-053 (magenta carbons) with PTP4A3. Hydrogen bonds are shown with yellow dashes, and WPD
loop residues W68PFDD72 are indicated by the red cartoon. For reference, active site residue C104 is shown with cyan carbons.
www.impactjournals.com/oncotarget
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Therefore, PTP4A3 thermal denaturation profiling was
conducted using SYPRO orange dye, an environmentally
sensitive fluorophore that exhibits increased fluorescence
on binding to hydrophobic protein segments. A Tm of 50.5
± 0.6ºC (n = 3) was obtained for the apo protein lacking
the ligand, while adding JMS-053 (100 μM) produced
a ∆Tm of 3.0ºC or a destabilizing effect against PTP4A3
indicative of ligand binding [21] (Figure 2E). This ∆Tm
exceeded the 1.7oC shift seen with a similar concentration
of the much less potent thienopyridone. The negative
control JMS-038 (100 μM) showed no effect on PTP4A3
stability. The recently available X-ray structure of
PTP4A3 in a complex with CNNM3 (PDB 5TSR) was
used to identify possible PTP4A3 binding modes for
JMS-053 [22]. Based on computational docking studies
with an energy refined structure, a putative binding site
in the closed conformation was identified. In agreement
with a noncompetitive mechanism (Figure 2D and 2F),
the putative allosteric site is removed from the active
site, and is located in a pocket that is flanked by the α3,
α4, and α6 helices, and the WPD loop. As the highly
flexible WPD loop clamps down on the active site, the
imine moiety of the inhibitor can engage in a hydrogen
bond with D72. As a result, this acidic residue would

no longer be available to support enzymatic activity
through interactions with catalytically important P-loop
residues C104 and R110 [23]. Moreover, this tight, well
desolvated inhibitor binding mode is predicted to hold the
WPD loop in the closed conformation via: 1) hydrogen
bonds between the compound’s pyridinedione oxygens
and the side chain amine and hydroxyl groups of residues
K144 and Y148, respectively, 2) π-stacking between the
thienopyridinedione and the Y148 side chain aromatic
ring, and 3) favorable π-π and hydrophobic contacts
between the inhibitor’s phenyl substituent and the aromatic
side chains of residues F70 and W84, as well as the alkyl
side chains of residues P76, V80, V81, L85, L114, and
L117, respectively. The proposed JMS-053 binding mode
(Figure 2F) suggests that the thienopyridone structure is
less active because it cannot engage in a hydrogen bond
with K144, while JMS-038 is void of activity because it
lacks the ability to orient in the proposed binding site such
that a hydrogen bond with D72 is established. Notably, all
of the proposed JMS-053 amino acids contacts, with the
exception of V80, are conserved across all three PTP4A
family members, which is consistent with this compound’s
inhibitory profile.

Figure 3: PTP dendrograms. Panel A. PTP phylogenetic tree of the 14 amino acids in the active site as described by Almo et al. [49],

depicting in red the PTPs tested for in vitro inhibition by JMS-053. JMS-053 inhibitory activity was tested on those phosphatases indicated
in red. The blue branches indicate tyrosine phosphatases and the orange branches are the dual specificity phosphatases. Panel B. The
phylogenetic tree represents the alignments of the longest isoform of the full length PTP as described by St-Denis et al. [50]. Marked in red
are the PTPs that were assayed in this project. Panel C. The phylogenetic tree represents the alignments of the longest isoform of the full
length dual specificity phosphatase with assayed phosphatases indicated in red.
www.impactjournals.com/oncotarget
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PTP4A3
inhibition
normalizes
transendothelial electrical resistance (TEER) after
vascular endothelial growth factor (VEGF) or
lipopolysaccharide (LPS) challenge

to elevated levels of VEGF in the tumor microenvironment
[25]. Because a marked in vivo reduction in VEGFinduced vascular permeability has been observed in
mice lacking PTP4A3 [13], the impact of JMS-053 on
the integrity of MVEC barrier function was evaluated.
Barrier function was measured by differences in transendothelial electrical resistance (TEER), a method that
has been repeatedly demonstrated to reflect changes in
macromolecular permeability and allows for continuous,
quantifiable, real-time monitoring of barrier function [26,
27]. Exposure of MVECs to VEGF (100 ng/mL) induced
a profound disruption or “leakiness” of the endothelial
barrier function that persisted for at least 22 h (Figure
4A). The precipitous decrease in endothelial barrier
integrity after VEGF treatment was normalized when
MVEC were pretreated for 2 h with 5 µM JMS-053 and

The vascular endothelium regulates macromolecular
and cellular trafficking through the vessel walls.
Enhanced vascular endothelial permeability is associated
with OvCa pathogenesis and malignant ascites fluid
formation, a key characteristic of OvCa that is often
present at diagnosis [24]. Many substances increase transendothelial permeability including growth factors, such
as VEGF, proinflammatory factors, such as cytokines,
and exogenous substances like bacterial LPS. The loss of
endothelial barrier function could be due, at least in part,

Figure 4: Pharmacological inhibition of PTP4A3 normalizes VEGF- and LPS-induced decreases in transendothelial
electric resistance (TEER). Panel A. Confluent MVEC cells were treated with VEGF alone (▲), JMS-053 (5 μM) for 2 h before (■)
or 3 h after VEGF (100 ng/mL) () exposure (indicated by the black arrow). TEER was monitored for 24 h using ECIS. Resistance was
normalized to time 0. Data are expressed as mean ± SEM, N = 3, *p < 0.05 versus vehicle control.  Panel B. Confluent MVEC cells
were pretreated with (■) or without (▲) JMS-053 (5 μM) and 24 h later challenged with LPS (0.5 EU/mL) (LPS treatment indicated by
the black arrow). Vehicle alone treated cells are indicated with the  symbol. TEER was monitored over time using ECIS. Resistance was
normalized to time 0. Data are expressed as mean ± SEM, N = 3, *p < 0.01 versus control. Panel C. Confluent MVEC were pretreated
with 5 μM Compound 43 (■) or vehicle control (▲) 2 h before 0.5 EU LPS (LPS treatment indicated by the black arrow) followed by
continuous exposure to either Compound 43 or vehicle control or they were treated 3 h after LPS with 5 μM Compound 43 (■). Vehicle
alone treated cells are indicated with the  symbol. TEER was monitored continuously using ECIS. Data are expressed as the mean ±
SEM, N = 4. *p < 0.01 versus control. Panels D. and E. The effect of JMS-053 on the LPS induced RhoA activation and Rac1 deactivation
by phosphorylation. Quantification of Western blot analysis of active RhoA, RhoA, active Rac1 and Rac1 in human MVEC pretreated for
24 h with vehicle (DMSO) or JMS-053 (5 µM) prior to treatment with vehicle or LPS treatment (0.5 EU/mL) for 1 h. Protein levels were
normalized to total RhoA or Rac1. Signal intensity of active RhoA and Rac1 was quantified by densitometry. *p < 0.05 versus vehicle (twoway ANOVA). Data plotted as mean ± SEM. N = 3.
www.impactjournals.com/oncotarget
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then continuously exposed to the compound (Figure 4A).
Post-treatment with JMS-053 at 3 h after VEGF exposure
normalized endothelial barrier function, indicating the lack
of a requirement for pretreatment (Figure 4A).
MVEC barrier dysfunction is also caused by LPS
and is mediated by RhoA activation [28]. The loss of
MVEC barrier is frequently caused by changes in the
actin cytoskeleton where cortically distributed actin is rearranged to form stress fibers via activation of RhoA and
a decrease in Rac1. Exposure to JMS-053 24 h prior to
LPS treatment prevented LPS-induced disruption of the
endothelial barrier function (Figure 4B). There was no
observed mitigation of LPS-induced vascular permeability
with JMS-053 treatment 3 h after LPS exposure.
Protection and mitigation of VEGF-induced increased
endothelial permeability was also observed with a recently
described inhibitor of PTP4A trimerization Compound 43
[7] (Figure 4C), which is structurally and mechanistically
quite distinct from JMS-053. This finding provided strong
orthogonal support for a role of the PTP4A family in the
regulation of endothelial permeability. JMS-053 treatment
blocked both the LPS-mediated RhoA activation and the
LPS-mediated reduction in Rac1 activation (Figure 3D-

3E). Collectively, these data suggest PTP4A phosphatases
have a regulatory role in endothelial barrier function
through the RhoA-Rac1 axis.

JMS-053 inhibits OvCa proliferation, spheroid
viability, and migration
The antiproliferative effects of JMS-053 were
compared to the nonspecific PTP4A3 inhibitor BR-1
[29] and thienopyridone [18] using OvCa cells plated as
a monolayer in cell culture microtiter plates and treated
with compounds for a total of 48 h. The most sensitive
cell line was A2780, with an IC50 for JMS-053 of 600 nM
(Table 3). OvCa cells that are resistant to either cisplatin
or paclitaxel remained sensitive to JMS-053. Moreover,
JMS-053 was 30-44 fold more potent than BR-1 in
inhibiting the growth of some of the OvCa cell lines and
was on average 8-fold more potent that thienopyridone
(Table 3). The negative control compound JMS-038 did
not significantly inhibit the growth of any of the OvCa
cell lines at concentrations as high as 50 µM. Response
to JMS-053 was unrelated to the population doubling
time as illustrated by the faster growing A2780CP20

Figure 5: Effect of JMS-053 and control compound treatment on OvCa cell line and human normal ovarian epithelial
cell spheroid growth. Representative IC50 curves for JMS-053 () and control compound ( ) JMS-038, a structurally related inactive
JMS-053 analog. Panel A. Relationship between PTP4A3 mRNA expression and IC50 values for JMS-053; Panel B. HeyA8; Panel C.
HeyA8-MDR; Panel D. A2780; Panel E. A2780CP20; Panel F. SKOV3; Panel G., SKOV3IP1; Panel H. SKOV3TRIP2; Panel I. OVCAR4;
Panel J. COV362: and Panel K. HI0-180 normal ovarian epithelial cells. Independent assays (N = 3) with N = 4 replicates.
www.impactjournals.com/oncotarget
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cells, which have a doubling time of 19.3 h and an IC50
of 1.1 ± 0.7 µM, compared to the parental A2780 cells,
which had population doubling time of 27.7 h and an IC50
of 0.6 ± 0.7 µM. JMS-053 did not inhibit the growth of
IMR90 fibroblasts. We observed a correlation between
the IC50 values and PTP4A3 expression (Figure 5A) but
we have been unsuccessful in quantifying endogenous
PTP4A3 protein levels in these cells. Others [30] have
demonstrated posttranslational control of PTP4A3 protein.
Moreover, PTP4A3 phosphatase activity is regulated by
SRC-mediated phosphorylation on Y53 [31], which adds
yet another level of complexity to the analysis.
Because OvCa often presents with ascites fluid
containing cancer cell aggregates, JMS-053 was evaluated
using relevant OvCa spheroids and a 48 h exposure.

OvCa cell line spheroids adopted varied morphological
features (Supplementary Figure 2). HeyA8 spheroids
were most responsive to JMS-053 with an IC50 value of
0.8 µM, and the paclitaxel-resistant HeyA8-MDR cells
retained sensitivity to JMS-053 with an IC50 of 3.5 µM
(Figure 5B-5C, Figure 6A, Table 3). A2780, A2780CP20,
SKOV3IP, SKOV3TRIP2, A2780, A2780CP20, COV362
and OVCAR4 cells had IC50 values between 1.1-5.5 µM
(Figure 5D-5E, 5G-5J, Table 3, Supplementary Figure
3). The least responsive was the SKOV3 parental cell
line with an IC50 value of 10.5 µM (Figure 5F, Table 3).
JMS-053 did not reduce normal human ovarian HI0-180
epithelial cells survival at concentrations up to 25 µM,
suggesting minimal toxicity at least against this nontumorigenic cell population (Table 3, Figure 5K). A 48 h

Figure 6: Genetic and pharmacological inhibition of PTP4A3. Panel A. JMS-053 but not JMS-038 inhibited HeyA8 cell spheroid

growth. Images were taken of the spheroids 48 h after plating and 24 h after compound addition. Bar = 100 μm. Panel B. Quantification
of JMS-053 effects on spheroid area. HeyA8 cells were incubated and treated with different concentrations of JMS-053 () or control
compound JMS-038 ( ). Brightfield spheroid images were captured 48 h after compound exposure and spheroid area was quantified using
Harmony software. Panel C. Scratch wound assay. JMS-053 inhibited HeyA8 migration after wounding. Images of the cells were taken
of the vehicle, JMS-053, and JMS-038 treated HeyA8 cell monolayers 0 and 15 h after the longitudinal scratch. Panel D. Suppression of
PTP4A3 mRNA levels by shRNA. Treatment of HeyA8 cells with scrambled (SCR) or two different PTP4A3-targeted shRNA for 48 h
decreased PTP4A3 mRNA, as measured by qRT-PCR. Panel E. Quantification of migration inhibition by shRNA. Confluent HeyA8 cells
expressing shRNA were longitudinally wounded with a pipet tip and cell migration was measured after 14 h by determining the open area
remaining from the scratch using multiple points of the cell front and ImageJ Fiji software. Panel F. Quantification of inhibition of cell
migration by JMS-053. Confluent HeyA8 cells were longitudinally wounded with a pipet tip and cell migration was measured 14 h later as
described above. JMS-053 but not JMS-038 blocked the migration of HeyA8 cells. *p < 0.05, N = 3.
www.impactjournals.com/oncotarget
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JMS-053 suppresses RhoA activation in OvCa
cells

exposure to the control compound JMS-038 did not show
any effects at concentrations up to 50 µM in any cell lines.
PTP4A3 overexpression promotes, and genetic
deletion reduces, cancer cell migration [10, 13].
Consistent with this observation, JMS-053 significantly
inhibited HeyA8 cell migration in a scratch wound assay
at concentrations as low as 750 nM (Figure 6B-6C).
Similarly, shRNA knockdown of PTP4A3 also diminished
HeyA8 cell migration, supporting the specificity of
the JMS-053-induced response (Figure 6D-6E). The
substantial difference in cellular IC50 values versus the in
vitro PTP4A3 IC50 value could be due to a combination
of factors, including cell membrane permeability,
intracellular compartmentalization, protein binding, and
compound degradation.

The phenotypic impact of genetic and pharmacologic
PTP4A3 inhibition prompted us to investigate what
changes in cell signaling drive these PTP4A3-dependent
cellular behaviors. RhoA activation is known to be
integral to the promotion of growth, migration, and
dissemination of tumor cells [32], and elevated PTP4A3
expression levels are reported to alter RhoA activity [10,
12, 32]. Therefore, the impact of JMS-053 treatment on
the activation of RhoA in HeyA8 cells was investigated.
HeyA8 cells were serum-starved overnight and then pretreated with JMS-053 (0.1-1 µM) or vehicle for 30 min
followed by a 30 min exposure to medium supplemented
with 10% FBS to stimulate RhoA activation in the
presence of either JMS-053 or vehicle. JMS-053 treatment

Figure 7: JMS-053 inhibits RhoA activation in HeyA8 cells and has antitumor activity. Panel A. Cells were starved in

serum-free RPMI 1640 for 24 h, then activation of RhoA was induced by exposure to 10% serum. Cells were pre-treated with indicated
concentrations of compounds for 30 min prior to serum stimulation and for 30 min while being stimulated with medium containing 10%
FBS. GTP bound RhoA in equal amounts of total lysate was quantified by a luminescence based G-LISA RhoA Activation assay. Treatment
with 0.1-1 μM JMS-053. Constitutively active RhoA was used as a positive control for the binding of GTP-RhoA to G-LISA. The data were
expressed as relative luminescence units (RLU) and were the mean ± SEM (N = 4). Statistical significance was determined by one-way
ANOVA and Tukey’s multiple comparison test. *p < 0.05, n.s. = not significant. Panel B. Female, athymic nude mice with HeyA8-MDR
tumors were injected IP with vehicle or JMS-053 (10 mg/kg) daily for 5 days followed by two days without treatment and four additional
daily treatments (10 mg/kg). Error bars = SEM. *p < 0.05 (Mann-Whitney). Panel C. Body weight monitoring for 12 days indicates that
JMS-053 treatment did not cause significant weight loss.
www.impactjournals.com/oncotarget
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were present 8 h after the injection. The area under the
plasma concentration curve (AUC) was 4.425 h*µg/mL,
which indicates a sustained presence of compound. Female
nu/nu mice bearing IP HeyA8-MDR tumors were used,
because the IP implantation site is very representative of
the human disease [33]. Tumor bearing mice were treated
with vehicle or 10 mg/kg JMS-053 over a nine-day period.
IP OvCa tumors were observed in all vehicle treated mice
and in 7 of 9 JMS-053 treated mice. The tumors from
the mice treated with JMS-053 for nine days weighed
on average 45% less than those from the vehicle treated
group (Figure 7B). There was no significant difference in
the body weights of the mice in the two treatment groups
(Figure 7C), thereby indicating that JMS-053 was well
tolerated at the doses that were administered.

Table 2: Specificity profiling of JMS-053
Phosphatase
% Activity (Mean ± SD)
PTPRC (CD45)
88 ± 3
DUSP22
91 ± 6
PTPN7 (HePTP)
97 ± 3
ACP1 (LMPTP-A)
95 ± 4
LMPTP-B
99 ± 0
DUSP10 (MKP5)
87 ± 0
PTPN4 (PTP-MEG1) 100 ± 1
CDC25B*
52 ± 6
PTPN9 (PTP-MEG2) 88 ± 5
PTPN1 (PTP-1B)
90 ± 5
PTPN22
94 ± 2
PTPRB (PTPβ)
95 ± 5
PTPRM (RPTPμ)
80 ± 1
PTPN6 (SHP-1)
97 ± 11
PTPN11 (SHP-2)
100 ± 9
PTPN2 (TCPTP)
95 ± 3
DUSP13 (TMDP)
95 ± 1
DUSP3 (VHR)
87 ± 11
PTP4A1*
1±0
PTP4A2*
0±0
PTP4A3*
0±0
PP1α
75 ± 0
PP2A*
99 ± 0
PP5
96 ± 2
YopH (Yersinia)
86 ± 4
Lambda PP (Phage)
72 ± 3

DISCUSSION
Epithelial OvCa is the most lethal gynecological
cancer and, unfortunately, it is usually diagnosed at
advanced stages when treatment strategies are limited.
Despite an initial response to surgical debulking and
platinum chemotherapy, recurrent or relapsed disease
is common. Accumulation of ascites fluid enables the
dissemination of OvCa cells or spheroid aggregates along
the peritoneal cavity, a characteristic that differentiates
OvCa from other metastasizing epithelial-derived cancers.
The enhanced permeability of the tumor vasculature
allows for the accumulation of proteins, including growth
factors, cells, and fluid, and provides a rich tumorpromoting microenvironment. Thus, OvCa represents
a disease of hyperpermeability, angiogenesis, cellular
proliferation, and metastasis.
It has been postulated that the PTP4A phosphatases
have a nodal role in cancer cell growth, survival,
metabolism, migration, and invasion [17, 18]. In
endothelial cells, increased PTP4A3 expression has been
documented to enhance migration, tube formation, and
angiogenesis [13, 14]. PTP4A phosphatases interact with a
variety of protein partners, including cell surface receptors,
intracellular signaling effectors, actin skeleton proteins,
and ion channels [17]. Despite the relatively low in vitro
catalytic activity of PTP4A with artificial substrates, the
catalytic domain is functionally or structurally relevant
in oncogenesis because phosphatase-deficient mutant
proteins are unable to form tumors [34]. The generation of
a PTP4A-targeted pharmacological small molecule tool set
should help to uncover the mechanism by which PTP4A
phosphatases alter cancer cell biology.
JMS-053 is a unique, potent, and selective small
molecule antagonist of PTP4A3 in vitro phosphatase
activity that suppresses the migration and decreases the
viability of OvCa cells, and impedes the in vivo growth
of OvCa (i.e., HeyA8-MDR) xenografts. Our data are
consistent with JMS-053-mediated inhibition of RhoA,
a previously described effector in the PTP4A3 signaling

JMS-053 (1 µM) was profiled in vitro with 10 µM
DiFMUP as a substrate against 26 phosphatases. Assays
performed by a commercial vendor unless marked with
an asterisk. N=2.
caused a significant inhibition of RhoA activation at all
concentrations tested with an IC50 of 0.6 µM (Figure 7A).
Treatment of HeyA8 cells with the control compound
JMS-038 (1 µM) had no significant effect compared to the
DMSO vehicle control. Treatment with PTP4A3 targeted
shRNA reduced RhoA activation and JMS-053 (500 nM)
caused no further reduction in RhoA activation consistent
with PTP4A3 target engagement (Supplementary Figure
4).

JMS-053 treatment inhibits drug-resistant OvCa
tumor growth in vivo
Drug resistance remains a challenging aspect of
OvCa treatment. Therefore, in a pilot study, the in vivo
activity of JMS-053 was examined using a HeyA8MDR nude mouse tumor model. Mice readily tolerated
an IP dose of 10 mg/kg of JMS-053 and, based on an
independent pharmacokinetic study by SAI Life Sciences,
the maximum plasma concentration was reached within
30 min and plasma concentrations of 225 ng/mL (879 nM)
www.impactjournals.com/oncotarget
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Table 3: Effects of JMS-053 on OvCa monolayer proliferation and spheroid viability
Monolayer (IC50 µM)
Cell line
BR-1
Thieno-pyridone JMS-053 JMS-038 Doubling time (h)a
SKOV3
48.3 ± 9.1 28.8 ± 2.2
4.3 ± 1.1 >50
43.3
SKOV3IP1
35.2 ± 2.3 31.3 ± 8.5
3.7 ± 0.4 >50
27.8
SKOV3TRIP2
46.5 ± 0.3 >50
2.9 ± 0.6 >50
35.8
A2780*
26.4 ± 1.0 4.5 ± 0.6
0.6 ± 0.2 >50
27.7
A2780CP20**
17.3 ± 2
13.1 ± 06
1.1 ± 0.04 >50
19.3
HEYA8*
>50
47 ± 4.9
25.2 ± 8.5 >50
19.0
HEYA8-MDR** >50
>50
19.1 ± 6.0 >50
20.8
OVCAR4
48.5 ± 7.9 15.5 ± 2.4
1.5 ± 0.3 >50
39.8
COV362
NDb
ND
ND
ND
ND
IMR90
ND
ND
>50
>50
<24 hc
HI0-180
ND
ND
ND
ND
ND

Spheroid
JMS-053
10.5 ± 1.5
5.2 ± 0.7
5.5 ± 2.4
1.1 ± 0.5
1.6 ± 0.7
0.8 ± 0.3
3.5 ± 1.4
4.4 ± 2.8
1.6 ± 0.9
ND
>25

(IC50 µM)
JMS-038
>50
>50
>50
>50
>50
>50
>50
>50
>50
ND
>25

Monolayer and spheroid cells were treated for 48 h with compounds. * cisplatin resistant; **, paclitaxel resistant. Mean ±
SD µM. N=3.
a
One determination.
b
ND = not determined
c
From [43]
pathway [10, 12, 35]. Mechanistically, PTP4A1 has also
been shown to regulate RhoA activation by binding and
inhibiting the catalytic activity of p115 RhoGAP [9]. The
binding interaction has been assigned to amino acids 30120 of PTP4A1, which is 80% identical in PTP4A3 and
contains the catalytic site. Moreover, the proposed binding
sites for JMS-053 overlaps with the p115 RhoGAP binding
site.
The pharmacological phenocopying of effects
observed in PTP4A3 genetic knockdown models by
JMS-053 fortifies the hypothesis that PTP4A3 is a
viable molecular target for OvCa treatment [11, 13].
JMS-053 exposure also restored compromised barrier
function after VEGF or LPS challenge in MVECs, and
inhibited RhoA activation and sustained active Rac1, a
pharmacodynamic endpoint of undamaged membrane
permeability. Complementing these results, a structurally
distinct small molecule inhibitor of PTP4A trimerization
[7] also restored compromised barrier function.
RhoA GTPase has well defined roles in the
regulation of cytoskeletal dynamics. These, in turn,
impact cell cycle progression and proliferation, migration,
invasion- and metastasis, which are all key aspects of
cancer initiation and progression (reviewed in [32, 36]).
Thus, targeting PTP4A3, upstream of RhoA, can have
multi-faceted anti-tumor and anti-metastatic effects.
To a large extent, the endothelial barrier integrity is
regulated by the small GTPases, Rac1, and RhoA [37],
which cycle between inactive, GDP-, and active, GTPbound configurations. This cycle is regulated by GTPase
activating proteins, which increase the intrinsic rate
of GTP hydrolysis and guanine nucleotide exchange
factors, which in turn promote GTPases into the GTPbound state [38]. Rac1 and RhoA exert opposing effects
on endothelial barrier function by inducing different
www.impactjournals.com/oncotarget

patterns of cytoskeletal and cellular contact remodeling
[39], often leading to either endothelial barrier protection
(Rac1) or to endothelial barrier dysfunction (RhoA)
[40]. Activation of RhoA by inflammatory mediators,
including LPS, activates ROCK1/2, which consequently
phosphorylates myosin light chain kinase and leads to
actomyosin contraction, actin stress fiber formation, and
disruption of endothelial barrier integrity (reviewed in
[41]). It is notable that RhoA mediates the activation/
phosphorylation of the ezrin/radixin/moesin proteins
[42]. Ezrin is a putative phospho-substrate of PTP4A3,
suggesting that PTP4A3 may not directly dephosphorylate
ezrin; rather it may inhibit ezrin phosphorylation indirectly
via down-modulation of RhoA-ROCK activity [43].
Similarly, inhibition of PTP4A3 may also prevent myosin
light chain phosphorylation indirectly via RhoA inhibition.
Moreover, with small G-proteins, including RhoA, the rate
of nucleotide exchange is regulated by nucleotide-bound
magnesium, which regulates the biological activity of the
GTPase [44]. The magnesium-based regulation of RhoA
is particularly relevant given recent work suggesting that
PTP4A phosphatases bind the magnesium transporter
cyclin M/ancient conserved domain protein (CNNM3)
via the PTP4A phosphatase active site, thereby regulating
intracellular magnesium transport [45].
In summary, pharmacological tools provide another
valuable method to dissect the role of domains in enzymes
and provide an orthogonal approach to genetic methods.
We believe that our compound, JMS-053, along with
other small molecules that have recently been described
[7], will likely be useful in testing the hypothesis that the
pharmacological inhibition of PTP4A3 can suppress OvCa
by targeting both the tumor cell directly and endothelial
cell hyperpermeability, which enables the infiltration of
cells and soluble proteins into the tumor microenvironment
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and results in an accumulation of ascites fluid.

previously used with human breast cancer [47], and
antigen retrieval was by High hP TR Flex solution (Dako)
at 97oC for 20 min. The immunogen for the PTP4A3
antibody was the first 100 amino acids of the protein,
which are not identical to the first 100 amino acids in
PTP4A1 and PTP4A2. It is assumed that this amino
acid difference precludes cross reactivity with PTP4A1
and PTP4A2, but we cannot exclude that possibility.
Tumor morphological classification was performed
in accordance with the American Joint Committee on
Cancer staging system. The study was approved by the
Institutional Human Subjects Protection Review Board at
the University of Virginia and carried out in accordance
with their standards.

MATERIALS AND METHODS
Compounds and reagents
Thienopyridone, Compound 43, JMS-053, and JMS038 (Figure 2A) were synthesized as previously described
[7, 19]. DiFMUP was purchased from ThermoFisher
Scientific (Waltham, MA). Dimethyl sulfoxide (DMSO)
was obtained from VWR (Radnor, PA). All other reagents
were obtained from Sigma-Aldrich unless otherwise
indicated.

In vitro biochemical analysis of JMS-053 and
thienopyridone

Ovarian cancer cell lines
HeyA8, HeyA8-MDR, A2870IP2 (referred to as
A2870 throughout), A2780CP20, COV362, SKOV3,
SKOV3IP1, SKOV3TRIP2, and HI0-180 cells were
obtained from Dr. Anil Sood (MD Anderson Cancer
Center, Houston, TX) and have been described previously
[46]. COV362 were obtained from Sigma-Aldrich (St.
Louis, MO). All cell lines were authenticated by short
tandem repeat DNA profiling prior to experimental
studies. OVCAR4 cells were obtained from Charles
River Laboratories (New York, NY). All cells were
maintained in RPMI (Life Technologies, Grand Island,
NY) supplemented with 10% fetal bovine serum (FBS),
with no antibiotics, and were passaged <20 times.

PTP4A3 activity assays were performed in triplicate
in 384 well Greiner bio-one black microtiter plates as
previously described [19] with recombinant His6-tagged
PTP4A3 and substrate DiFMUP (15 µM) incubated at
25°C for 30 min in 40 mM Tris-HCl (pH 7.0), 75 mM
NaCl, 2 mM EDTA, and 4 mM DTT buffer. Reversibility
assays were performed in a 100 μL total volume using the
same assay conditions. His6-tagged PTP4A3 (1.25 μg) was
pre-incubated for 30 min with 10X the IC50 of JMS-053
(180 nM) and then diluted to 1X IC50 (18 nM). Reactions
were initiated with the addition of 45 µL of substrate for
a final DiFMUP concentration of 4 μM (Km). Phosphatase
activity was expressed as a percent maximal activity.
To determine the competitive nature of the inhibition,
we used a previously described assay [19] with fixed
concentrations of the compounds and DiFMUP substrate
concentrations that were varied from 2.5-25 μM and the
data were analyzed with GraphPad Prism version 7.00
(GraphPad Software, La Jolla CA).

The Cancer Genome Atlas datamining
The ovarian serous cystadenocarcinoma dataset
was accessed and mined through the Cancer Genome
Atlas (TCGA) Research Network (Provisional 2017)
(http://cancergenome.nih.gov/). Tumor samples with
corresponding RNAseq (307 patients) and U133
microarray mRNA data (535 patients) were used for
subsequent analysis.

Phosphatase specificity of JMS-053
The inhibition specificity of JMS-053 was
determined for 26 phosphatases by Eurofins (Dundee,
Scotland, UK) with their PhosphataseProfilerTM platform
using 10 µM DiFMUP as a substrate and fluorescent
intensity at A360EX/A450EM. Inhibitory effects were
calculated as the mean percent phosphatase activity
remaining compared with the activity of the vehicle
control. Kinase profiling of JMS-053 was performed
by Luceome Biotechnologies (Tucson, AZ) using their
luciferase-based KinaseSeekerTM platform. JMS-053
was evaluated at 1 µM in duplicate in both profiling
platforms. The CDC25B assays were performed with a
slight modification to our previously described methods
[48] using recombinant enzyme and the substrate DiFMUP
at ~3X the Km (150 µM). PTP4A1 and PTP4A2 assays

Immunohistochemical staining and scoring of
patient OvCa tumors
Fifty-seven high-grade serous ovarian cancer
specimens were obtained after surgical resection and
prior to radiation or chemotherapy. Formalin-fixed
paraffin embedded patient samples were tissue sectioned,
and immunohistochemical stained for PTP4A3 by the
University of Virginia Biorepository and Tissue Research
Facility Core following standard procedures. Tissue and
tumor sections were stained with anti-PTP4A3 (5 µg/
mL, Abcam (ab82568), Cambridge, MA), which was
www.impactjournals.com/oncotarget
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were performed in triplicate in 384 well microtiter plates
using the same conditions as for PTP4A3 as indicated
above. PP2A was a gift from Professor David Brautigan
(University of Virginia) and was assayed with the substrate
DiFMUP at ~3X KM (150 µM) in 120 mM Tris-HCl (pH
7.0), 225 mM NaCl, 0.1% BME, and 0.1% BSA buffer. All
assays were incubated for 30 min at 25oC. Fluorescence
was measured using a SpectraMax M5 plate reader
(Molecular Devices, LLC, Sunnyvale, CA) at A358EX/
A455EM. The human active site phosphatase phylogenetic
tree comprising 14 amino acids (XXXX(His)(Cys)
XX(Gly)XX(Arg)XX, where X is any amino acid) was
modeled on the published [49] dendrogram supplemented
with the alignment of other PTPs tested using ClustaW2
and the full length amino acid sequence trees were
modeled using the longest isoform [50].

chain torsions. The Maestro refine loops algorithm was
applied to loop residues 68 - 78, followed by all atoms
minimization of the complex using conjugate gradients in
Insight 2005 until the norm of the gradient was < 0.001
kcal/Å.

Thermal shift biophysical validation of JMS-053
binding
PTP4A3 melting curves were obtained at a protein
concentration of 16 μM (50 mM Tris 150 mM NaCl, 1
mM DTT pH 7.4) with 20X SYPRO orange (Invitrogen)
and a ligand concentration of 100 μM. Fluorescence was
monitored using a QuantStudio 6 Flex real-time PCR
system (Applied Biosystems). Scans were measured from
25oC to 65°C at a scanning rate of 1°C/min. The data were
analyzed using Derivative methods to assess the melting
temperature (Tm) using Graphpad Prism as previously
described [52].

Computational studies
Drug-like properties for the compounds were
determined with Data Warrior (http://www.openmolecules.
org/datawarrior/). Chemical similarity analyses were
performed with PubChem (https://pubchem.ncbi.nlm.nih.
gov) and ChemSpider (www.chemspider.com) using a
2D Tanimoto score of ≥0.8. Modeling software Maestro
version v11 (Schrödinger, LLC, New York, NY), and
Insight 2005 and Discovery Studio v16 (both: Dassault
Systèmes BIOVIA, San Diego, CA), operating on a
Dell (Round Rock, TX) Precision T7600 with Red Hat
(Raleigh, NC) Enterprise Linux 6.7, were used for all
modeling studies. The three-dimensional (3D) coordinates
of PTP4A3 were extracted from PDB entry 5TSR [22];
the 3D coordinates of inhibitor JMS-053 were obtained
from the Cambridge Crystallographic Data Centre (CCDC
number 1476250) [19]. The structure of PTP4A3 was
energy refined in Insight 2005 using a previously reported
strategy starting with hydrogens only minimization,
followed by side-chain relaxation, and finally, all atoms
optimization until the norm of the gradient was <0.001
kcal/Å [51]. The RMSD of the energy refined structure
versus the starting X-ray structure was 1.29 Å, which
was well within crystallographic resolution. Maestro
and Discovery Studio binding site detectors were used
to identify a location for JMS-053 binding in a cavity
(volume ~ 350 Å2) surrounded by helices α3, 4, 6 and
loop residues 68 - 78. This cavity was chosen for docking
studies given that its location was removed from the active
site, yet in contact with the critical WPD loop. Docking of
the inhibitor in this site was guided by the constant scoring
of favorable and unfavorable intermolecular, atom-atom
contacts using the HINT program (implemented in
Discovery Studio) as described previously [51]. Briefly,
an systematic optimization of the binding pose applied
iterative steps and manual adjustments to the inhibitor
in Cartesian space, as well as to inhibitor bond torsions,
in conjunction with adjustments to amino acid side
www.impactjournals.com/oncotarget

Real-time quantitative polymerase chain reaction
(RT-qPCR)
Total RNA was purified from HeyA8 cells using an
RNAeasy Plus RNA isolation kit per the manufacturer’s
protocol (Qiagen, Valencia, CA). A total of 500 ng of
mRNA were converted to cDNA using the RT2 first strand
synthesis kit (Qiagen). Primers were obtained from Qiagen
and PTP4A3 amplification was performed at a final primer
concentration of 400 nM. Real-time monitoring of the
qPCR reaction was performed on a BioRad CFX Connect
thermocycler with RT2 SYBR Green ROX Mastermix
(Qiagen). The program was run at 95°C for 10 min, and 40
cycles at 95°C for 15 sec and 60°C for one min. PTP4A3
gene expression was normalized to human GAPDH and
β-actin.

Two-dimensional (2D) viability assay
Compounds were tested for their effects on viability
using OvCa cell lines and a resazurin-based CellTiter
Blue (Promega, Fitchburg, WI) 2D assay system with
previously described procedures [53]. All OvCa cell
lines were cultured in complete growth medium with
500 cells/22 μL being seeded into each well of a 384
well black/clear microtiter plate (VWR). Compounds (3
μL) were added immediately to produce a final DMSO
concentration of 0.5% matching the vehicle control
final DMSO concentration. The positive control wells
had a final concentration of 10% DMSO. The microtiter
plates were incubated for 44 h (37°C, 5% CO2) at which
time 5 μL of the resazurin-based CellTiter Blue reagent
were added. Following an additional 4 h of incubation
(37°C, 5% CO2), data were captured on a SpectraMax
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M5 multimode plate reader with an A560EX/A590EM.
IC50 values were calculated using GraphPad Prism 7.0
software.

transfection and reseeded in 12 well microtiter plates at
2 x 105 cells/well and grown to confluency. The scratch
wound assay was carried out as described above.

Spheroid growth and formation assays

Measurement of endothelial barrier function

Exponentially growing OvCa cells were harvested
and seeded (100 cells/22 µL for HeyA8, HeyA8-MDR
and HI0-180, and 250 cells/22 µL for OVCAR-4, A2780,
A2780CP20, SKOV3, SKOV3IP1, SKOV3TRIP2, and
COV362) in each well of a 384 well ultralow attachment
U-bottom microplate (Corning, Corning, NY). Plates
were incubated for 24 h (37oC at 5% CO2) to allow
for spheroid formation. Compounds (3 μL) were then
added in final DMSO concentrations of 0.5%, as was
the vehicle control (0.5% DMSO). The positive control
wells contained 10% DMSO. The microtiter plates were
incubated for 48 h (37°C, 5% CO2) and 25 μL of the
CellTiterGlo 3D reagent (Promega, Fitchburg, WI) was
added. Plates were incubated with shaking for 30 min
at room temperature. Luminescence data were captured
on a SpectraMax M5 multimode plate reader. JMS-053
effects on OvCa spheroid size were determined using a
PerkinElmer Operetta CLS high content image analysis
system (PerkinElmer, Waltham, MA). Exponentially
growing HeyA8 cells were harvested, seeded (100 cells/22
µL), incubated, and treated with compound as described
above. Brightfield spheroid images were captured 48
h after JMS-053 or JMS-038 exposure using a 10X
objective. Spheroid area was quantified using Harmony
software (PerkinElmer). Data were analyzed and IC50
values calculated using GraphPad 7.0.

The barrier function of endothelial cell monolayers
grown on electrode arrays was estimated by our previously
described [26, 27] electric cell-substrate impedance
sensing (ECIS) method using an ECIS model 1600R
from Applied BioPhysics (Troy, NY). Experiments were
conducted on cells seeded at a density of 6 x 104 cells/well
in 8W10E+ arrays that achieved at least 800Ω baseline
steady-state resistance and capacitance between 22-29
nanofarads at a frequency of 4000Hz. Each 0.6 mL well
of the 8 well arrays had 40 small gold film surface active
electrodes (2 mm2 area) and a large counter electrode.
A uniform confluent endothelial monolayer reduced the
amount of current flowing across the gold electrodes to
the counter electrode, and thus increased the resistance.
The transendothelial electrical resistance (TEER)
measured dynamically across the monolayer reflected
the combined resistance between the ventral surface of
the cell and the electrode, reflective of focal adhesion,
as well as the resistance between cells. Intercellular
gaps increase current flow and reduce resistance. Thus,
a change in TEER represented a change in cell-cell
adhesion and/or cell-matrix adhesion. All experiments
used primary human lung microvascular endothelial cells
(MVEC) that were harvested, identified, and cultured
in-house from fresh specimens obtained from patients
undergoing pneumonectomy or lobectomy, as previously
described [54] and in accordance with our Institutional
Review Board criteria. MVEC were exposed to 100 ng/
mL VEGF, 0.5 endotoxin units (EU) LPS, or vehicle
control. In some studies cells were pre-treated and then
continuously treated with 5 μM of JMS-053, JMS-038, or
Compound 43. In other studies, cells were treated 3 h after
exposure to VEGF or LPS. Experiments were performed
in quadruplicate and data were expressed as mean values
± SE. One-way or two-way ANOVA with Bonferroni
post-hoc test was performed to determine statistically
significant differences among groups (p < 0.05).

Migration assay
OvCa cell migration was quantified using our
previously described in vitro scratch wound healing assay
[13]. For compound treatment studies, HeyA8 cells were
grown to confluent monolayers in 24 well tissue culture
plates (BD Biosciences, San Jose, CA). Each well (n =
3 per compound or control treatment) was scratched
longitudinally with a pipette tip and incubated for 14 or
15 h to enable gap closure. Images of the cell migration
front were captured and the migration area was determined
by measuring the distance between cell fronts at multiple
points in the images using ImageJ Fiji software and then
calculating the open area remaining from the scratch.
For shRNA studies, HeyA8 cells were seeded at
5 x 105 cells per well of a six well tissue culture dish.
At 90% confluency, cells were forward transfected
with 2.5 µg scrambled or PTP4A3-targeted pGFP-CshLentiRNA encoding plasmids (Origene Technologies,
Rockville, MA) complexed with lipofectamine 3000 (1:3)
(ThermoFisher). After 16 h, culture medium was replaced.
Cells were harvested by trypsin treatment at 32 h postwww.impactjournals.com/oncotarget

RhoGTPases activity assay
RhoA activation in HeyA8 cells was detected by
the luminescence formatted RhoA G-LISA Activation
Assay (Cytoskeleton Inc., Denver, CO), according to
manufacturer’s instructions. Following a 24 h serum
starvation in RPMI supplemented with 0.1% fattyacid free bovine serum albumin, HeyA8 cells at ~60%
confluence were pretreated in serum-free medium for 30
min with compounds in a final DMSO concentration of
0.5%, as was the vehicle control. HeyA8 cells were then
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For in vivo antitumor experiments, HeyA8-MDR
cells in exponential growth phase were detached from
the monolayer with 0.25% trypsin and 20 µg/mL EDTA
in PBS and resuspended in 10% FBS-containing RPMI,
pelleted, and resuspended in serum-free RPMI at a
concentration of 5 x 106 cells/mL. Female athymic nude
mice (Envigo, Dublin, VA) were injected intraperitoneally
(IP) (200 µL/injection) with cells and after one week mice
(n = 10 per group) were randomized for treatment with
vehicle (20% 1-methyl-2-pyrrolididone, 25% Kolliphor
HS 15, and 55% 1X phosphate buffered saline) or with
vehicle plus 10 mg/kg JMS-053. Mice were treated IP
daily (100 µL/ injection) for 5 days with a 2-day holiday
followed by 4 additional days of treatment before being
sacrificed. All tumors were excised and weighed. All in
vivo procedures were performed using the University of
Virginia approved IACUC protocols. Animal care was
administered in accordance to guidelines established by
the American Association for Accreditation of Laboratory
Animal Care.

stimulated for 30 min with RPMI containing 10% FBS
and the compounds in a final DMSO concentration of
0.5% and harvested on ice. Total protein was determined
using Precision Red Advanced protein assay reagent
(Cytoskeleton Inc.). Fifteen µg of cell lysate protein
per Rho-GTP affinity well were incubated at 4°C for
30 min on an orbital shaker to facilitate binding. As a
positive control, 1 ng of purified recombinant RhoA was
bound to the affinity well. The provided primary and
secondary antibodies were used at a 1:250 and 1:500
dilution, respectively. Luminescence data were captured
on a SpectraMax M5 multimode plate reader set to 50
ms integration time following 2 min incubation with
luminescence detection reagent.
Human MVEC were pretreated with vehicle
(DMSO) or JMS-053 (5 µM) prior to vehicle or LPS
treatment (0.5 EU/mL) for 1 or 24 h. MVEC RhoA
activation was detected using the bead pull-down format
RhoA Activation Assay Biochem Kit (Cytoskeleton Inc.).
Cells were lysed in CelLyticM Lysis Reagent and total
protein in the lysate was determined with a Pierce BCA
protein assay (ThermoFisher Scientific). Five hundred µg
of total cell lysate protein were incubated at 4°C with 80
µg Rhotekin-RBD protein beads for 1 h rotating. After
precipitation, the complexes were washed four times with
the wash buffer, eluted in 2X SDS-PAGE sample buffer,
immunoblotted, and probed with RhoA antibody. GTPbound RhoA detection was performed using a monoclonal
rabbit RhoA antibody (Cell Signaling, no. 2117) [26].
Proteins were visualized using a LICOR Odyssey CLx
imaging system (Lincoln, NE). Aliquots were taken
from supernatants prior to precipitation and were used to
quantify total RhoA. Rac1 activity was determined using
the Rac Activation Assay Biochem Kit (Cytoskeleton Inc.,
BK-035) per the manufacturer’s instructions. Secondary
mouse and rabbit antibodies were purchased from LICOR.
ImageJ software was used to perform densitometry of
immunoblots. All data were expressed as mean values
± SE. Student’s t-test or one-way or two-way ANOVA
with Bonferroni post hoc test was performed to determine
statistically significant differences among groups (p <
0.05).

Statistical analysis
All statistical analyses were performed with
GraphPad Prism 7.0. Data are presented as average (mean)
± SD or SE. P values were calculated with Student’s t
test for comparisons involving two groups or one-way
or two-way ANOVA for comparisons involving >two
groups. P < 0.05 was considered statistically significant.
Each experiment is represented by at least three biological
replicates and three technical replicates (per independent
experiment).
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